Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.71 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.71 |
| ▸ | AXL | P30530 | 3/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.50 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226130 | 0.90 | MAP2K4 (0.61) | FGFR1FGFR2AXLPDPK1HSP90AB1 | |
| SCHEMBL5552470 | 0.89 | AXL (0.69) | FGFR1FGFR2AXLPDPK1HSP90AB1 | |
| SCHEMBL1663211 | 0.85 | AXL (0.60) | FGFR1FGFR2AXLPDPK1AURKA | |
| SCHEMBL12318475 | 0.81 | KDM4E (0.71) | FGFR1FGFR2AXLPDPK1AURKA | |
| SCHEMBL922069 | 0.79 | PDPK1 (0.65) | FGFR1FGFR2AXLPDPK1AURKA | |
| SCHEMBL6371302 | 0.79 | AXL (1.00) | FGFR1FGFR2AXLPDPK1AURKA | |
| SCHEMBL2860721 | 0.79 | AXL (0.61) | FGFR1FGFR2AXLPDPK1AURKA | |
| SCHEMBL421269 | 0.77 | JAK2 (0.77) | FGFR1FGFR2PDPK1FGFR3AURKA | |
| SCHEMBL1663652 | 0.75 | FGFR1 (0.68) | FGFR1FGFR2AXLPDPK1HSP90AB1 | |
| SCHEMBL2469031 | 0.75 | AXL (0.55) | FGFR1FGFR2AXLAURKAMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| CN-102656141-A | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | FGFR1 129/4885FGFR2 203/4885AXL 1200/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | FGFR1 43/4885FGFR2 79/4885AXL 448/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | FGFR1 43/4885FGFR2 79/4885AXL 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.